Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

SPRUCE BIOSCIENCES, INC. (SPRB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in CAHptain Study for Pediatric Classic CAH South San Francisco, Calif. – August 14, 2023 – Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. “Our goal with the POWER..."
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/15/2023 8-K Quarterly results
Docs: "Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome Complete – Topline Results Anticipated in Q3 2023 Cohort 1 for Phase 2 CAHptain Study in Pediatric Classic CAH Fully Enrolled South San Francisco, Calif. – May 15, 2023 – Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates. “I am pleased by the me..."
03/16/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates CAHmelia-203 in Adult Classic CAH Surpasses 50% Enrollment Private Placement Financing of $53.6 million in Gross Proceeds with Top-Tier Healthcare Investors Strategic Partnership and Exclusive Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Tildacerfont for CAH in Japan Private Placement Proceeds and Kaken Upfront Payment Expected to Extend Cash Runway Into 1H 2025 South San Francisco, Calif. – March 16, 2023 – Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and pro..."
02/09/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK SPRUCE BIOSCIENCES, INC. Warrant Shares: [_______] Issue Date: [____], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK certifies that, for value received, [_____________] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until 5:00 p.m. on [___], 2028 but not thereafter, to subscribe for and purchase from Spruce Biosciences, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following ter...",
"COMMON STOCK PURCHASE WARRANT SPRUCE BIOSCIENCES, INC. Warrant Shares: [_______] Issue Date: [____], 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [_____________] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until 5:00 p.m. on [___], 2028 but not thereafter, to subscribe for and purchase from Spruce Biosciences, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicat...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement , dated as of February 8, 2023, is made by and among Spruce Biosciences, Inc., a Delaware corporation , and the Purchasers listed on hereto, together with their permitted transferees . Recitals A. The Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act and/or Rule 506 of Regulation D as promulgated by the SEC under the Securities Act. B. The Purchasers, severally, and not jointly, desire to purchase from the Company, and the Company desires to sell to the Purchasers, upon the terms and conditions stated in this Agreement, shares of the Company’s common stock, par value $0.0001 per share , to certain Purch..."
01/09/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements...
12/02/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
Docs: "Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment Appointment of Saba Sile, M.D., as Vice President of Clinical Development"
08/10/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
04/08/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Re: Amendment to Offer Letter Dear Javier, This letter agreement amends the offer letter dated December 29, 2021 , between you and Spruce Biosciences, Inc. , as set forth below. The eighth paragraph of the Offer Letter is hereby amended and restated in its entirety as follows: “You will be entitled to participate in the Company's Severance and Change of Control Plan , a copy of which will be separately provided to you, provided that with respect to the Second Stock Option only, the vesting acceleration benefits under the Severance Plan applicable to a Change in Control Termination will only apply for a Change in Control with an effective date on or after the first anniversary of your Start Date.” Other than as provided in this Amendment, the terms and conditions of your emplo..."
03/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2001 Junipero Serra Blvd., Suite 640 Daly City, California 94014"
03/14/2022 8-K Quarterly results
Docs: "Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates Topline Safety Data from Cohort 1 of Pediatric Classic CAH Study Expected by 1H 2023 Will Charlton, M.D., M.A.S., Appointed Chief Medical Officer"
01/05/2022 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Offer Letter, by and between the Company and Javier Szwarcberg, M.D., MPH",
"Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise for Inducement Grant Outside of the Spruce Biosciences, Inc. 2020 Equity Incentive Plan",
"Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer – Samir Gharib, MBA, Promoted to President –"
09/15/2021 8-K Quarterly results
08/25/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
06/29/2021 8-K Quarterly results
05/24/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/22/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
01/06/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021 - CAHmelia Adult Classic CAH Program Underway in U.S. and Europe- -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second Half of 2021- -Initiation of Phase 2 Polycystic Ovary Syndrome Program Anticipated in Second Half of 2021- -New Patent Issuance Extends Tildacerfont Patent Exclusivity through 2038-"
11/18/2020 8-K Quarterly results
Docs: "Press Release of Spruce Biosciences, Inc."
10/14/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy